DXCM's Q2 earnings and revenues beat estimates as global demand, broader access and margin expansion fuel stronger 2026 ...

Shares of medical device company DexCom (NASDAQ:DXCM) jumped 10.9% in the morning session after the company reported strong ...

DexCom (NASDAQ:DXCM) reported second-quarter 2026 revenue growth of 13% from a year earlier, supported by continued demand ...

Selected devices will be exempt from certain premarket requirements while manufacturers collect real-world data through ...

Left unable to speak or walk after a malfunction, the 50-year-old feels the vulnerabilities in this technology needs to be ...

In a 2-pronged move, the FDA approved the sale of the Dexcom G6 integrated continuous glucose monitoring system for determining blood glucose levels and also classified the unit as a class II medical ...

Health Canada has granted authorisation for the Dexcom G7 15 Day continuous glucose monitor (CGM) for adults aged 18 years and older with diabetes. Offering 15.5 days of wear, the ...

Dexcom G7 15 Day is the longest‑lasting and most accurate 1-4 CGM system authorized by Health Canada, providing real-time glucose readings for an industry-leading 15.5 days 5. BURNABY, British ...

Diabeloop, a pioneer in therapeutic artificial intelligence for diabetes management, today announces that DBLG2 ...

Heald, a digital metabolic health platform, today announced that consumers who purchase a Dexcom Stelo or Abbott Lingo continuous glucose monitor (CGM) through Heald will now receive complimentary ...

Smartwatches still can’t measure blood sugar on their own, but AI-powered CGMs are changing how glucose data is tracked and used.